Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 01/22 03:04:48 pm
141.125 EUR   -0.09%
11:35aMERCK KGAA : Independant Research sticks Neutral
MD
07:12aMERCK KGAA : Barclays reaffirms its Neutral rating
MD
01/21MERCK KGAA : Kepler Cheuvreux remains its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck KGaA: Correction of a release from 25/03/2020 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

11/24/2020 | 04:37am EST

DGAP Voting Rights Announcement: Merck KGaA
Merck KGaA: Correction of a release from 25/03/2020 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

24.11.2020 / 10:35
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: Merck KGaA
Street: Frankfurter Str. 250
Postal code: 64293
City: Darmstadt
Germany
Legal Entity Identifier (LEI): 529900OAREIS0MOPTW25

2. Reason for notification
X Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
  Other reason:

3. Details of person subject to the notification obligation
Natural person (first name, surname): George Loening
Date of birth: 30 Jan 1966

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
19 March 2020

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 3.11 % 0.04 % 3.15 % 129242252
Previous notification n/a % n/a % n/a % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0006599905 0 4018061 0.00 % 3.11 %
Total 4018061 3.11 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
0 0.00 %
    Total 0 0.00 %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
CFD n/a n/a Cash 56989 0.04 %
      Total 56989 0.04 %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
X Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
George Loening % % %
Cooper Square Holdings II, LLC % % %
Cooper Square Fund II, L.P. % % %
- % % %
George Loening % % %
Cooper Square Holdings, LLC % % %
Cooper Square Fund, L.P. % % %
- % % %
George Loening % % %
Baxter Street Holdings, LLC % % %
Baxter Street Fund, L.P. % % %
- % % %
George Loening % % %
Baxter Street Holdings II, LLC % % %
Baxter Street Fund II, L.P. % % %
- % % %
George Loening % % %
SEG Partners Holdings, LLC % % %
SEG Partners Fund, L.P. % % %
- % % %
George Loening % % %
SEG Partners II Holdings, LLC % % %
SEG Partners Fund II, L.P. % % %
- % % %
George Loening % % %
SEG Blackwall Holdings, LLC % % %
SEG Blackwall Fund, L.P. % % %
- % % %
George Loening % % %
Sheridan Square Holdings, LLC % % %
Sheridan Square Fund, L.P. % % %
- % % %
George Loening % % %
Crosby Street Holdings, LLC % % %
Crosby Street Fund, L.P. % % %
- % % %
George Loening % % %
Select Equity GP, LLC % % %
Select Equity Group L.P. 3.11 % % %

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
23 Nov 2020



24.11.2020 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Internet: https://www.merckgroup.com/de

 
End of News DGAP News Service

1150135  24.11.2020 

fncls.ssp?fn=show_t_gif&application_id=1150135&application_name=news&site_id=zonebourse_sftp

© EQS 2020
All news about MERCK KGAA
11:35aMERCK KGAA : Independant Research sticks Neutral
MD
07:12aMERCK KGAA : Barclays reaffirms its Neutral rating
MD
01/21MERCK KGAA : Kepler Cheuvreux remains its Buy rating
MD
01/21MERCK KGAA : Bernstein remains Neutral
MD
01/21MERCK KGAA : JP Morgan maintains a Buy rating
MD
01/21MERCK KGAA : UBS reaffirms its Neutral rating
MD
01/21MERCK : Discontinues Phase III Clinical Trial For Lung Cancer Drug On Failure To..
MT
01/20MERCK KGAA : Credit Suisse gives a Buy rating
MD
01/20MERCK KGAA : Sell rating from Goldman Sachs
MD
01/20MERCK : Shares Fall After Announcement of Cancer-Drug Trial Interruption
DJ
More news
Financials
Sales 2020 17 362 M 21 125 M 21 125 M
Net income 2020 1 977 M 2 405 M 2 405 M
Net Debt 2020 11 147 M 13 562 M 13 562 M
P/E ratio 2020 31,0x
Yield 2020 0,99%
Capitalization 61 347 M 74 677 M 74 642 M
EV / Sales 2020 4,18x
EV / Sales 2021 3,88x
Nbr of Employees 58 077
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 139,28 €
Last Close Price 141,25 €
Spread / Highest target 19,6%
Spread / Average Target -1,40%
Spread / Lowest Target -28,5%
EPS Revisions
Managers and Directors
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Christian Raabe Independent Member-Supervisory Board
Edeltraud Glänzer Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA0.64%74 584
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD11.98%27 823
KYOWA KIRIN CO., LTD.-1.28%14 661
BETTA PHARMACEUTICALS CO., LTD.33.28%8 595
YUHAN CORPORATION-3.60%4 335
RECIPHARM AB (PUBL)3.92%2 773